Franklin Street Advisors Inc. NC Buys 100,000 Shares of FibroGen, Inc. (NASDAQ:FGEN)

Franklin Street Advisors Inc. NC raised its position in FibroGen, Inc. (NASDAQ:FGEN) by 100.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 200,000 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Franklin Street Advisors Inc. NC owned 0.20% of FibroGen worth $106,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Point72 DIFC Ltd grew its position in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the period. Doheny Asset Management CA purchased a new stake in shares of FibroGen in the second quarter worth about $48,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of FibroGen in the second quarter valued at approximately $130,000. Sei Investments Co. increased its holdings in FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 41,442 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in FibroGen during the 2nd quarter worth approximately $145,000. 72.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on FGEN shares. StockNews.com started coverage on FibroGen in a research report on Wednesday, January 1st. They issued a “hold” rating on the stock. William Blair reiterated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. Finally, HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a research report on Tuesday, December 17th.

FibroGen Price Performance

FibroGen stock traded down $0.01 during trading hours on Friday, reaching $0.64. The company had a trading volume of 1,523,068 shares, compared to its average volume of 2,034,973. FibroGen, Inc. has a 12-month low of $0.18 and a 12-month high of $2.93. The company has a 50-day moving average price of $0.42 and a 200 day moving average price of $0.51. The firm has a market cap of $64.46 million, a price-to-earnings ratio of -0.52 and a beta of 0.75.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the previous year, the firm posted ($0.52) EPS. As a group, research analysts expect that FibroGen, Inc. will post -0.86 earnings per share for the current year.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.